Literature DB >> 7684193

Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation.

H Haapasalo1, J Isola, P Sallinen, H Kalimo, H Helin, I Rantala.   

Abstract

Aberrant expression of the p53 suppressor gene was evaluated in 102 cases of astrocytic neoplasms. Immunohistochemical staining with a monoclonal antibody (DO-7) and a polyclonal antibody (CM-1) to p53 protein (both wild type and mutant) on formalin-fixed paraffin sections showed a strong correlation with malignancy grade. The staining was positive in 49% of malignant neoplasms (grades III and IV) and in 19 to 29% of grade II astrocytomas, whereas none of the grade I tumors were positive. p53 expression was significantly associated with proliferation rate determined by immunohistochemical proliferating cell nuclear antigen (PCNA)-staining (median PCNA-labeling index (%): 4.22 (DO-7-positive) versus 1.18 (DO-7-negative), P < 0.0001; 4.02 (CM-1-positive) versus 1.18 (CM-1-negative), P < 0.001). Interestingly, in the glioblastoma group (n = 44), p53-positive tumors had higher proliferation indices, suggesting that histologically similar tumors could be divided into prognostically different subgroups by immunohistochemical demonstration of aberrant p53 expression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684193      PMCID: PMC1886904     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  18 in total

1.  P53 in tumour pathology: can we trust immunocytochemistry?

Authors:  D Wynford-Thomas
Journal:  J Pathol       Date:  1992-04       Impact factor: 7.996

2.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

3.  Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.

Authors:  J Isola; T Visakorpi; K Holli; O P Kallioniemi
Journal:  J Natl Cancer Inst       Date:  1992-07-15       Impact factor: 13.506

4.  p53 protein expression in central nervous system neoplasms.

Authors:  M Barbareschi; P Iuzzolino; A Pennella; A Allegranza; G Arrigoni; P Dalla Palma; C Doglioni
Journal:  J Clin Pathol       Date:  1992-07       Impact factor: 3.411

5.  PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables.

Authors:  E Leonardi; S Girlando; G Serio; F A Mauri; G Perrone; S Scampini; P Dalla Palma; M Barbareschi
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

6.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

Authors:  J Bártek; J Bártková; B Vojtĕsek; Z Stasková; J Lukás; A Rejthar; J Kovarík; C A Midgley; J V Gannon; D P Lane
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

7.  Timing and role of p53 gene mutation in the recurrence of glioma.

Authors:  Y Hayashi; J Yamashita; K Yamaguchi
Journal:  Biochem Biophys Res Commun       Date:  1991-10-31       Impact factor: 3.575

8.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.

Authors:  B Vojtĕsek; J Bártek; C A Midgley; D P Lane
Journal:  J Immunol Methods       Date:  1992-07-06       Impact factor: 2.303

9.  p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma.

Authors:  A von Deimling; R H Eibl; H Ohgaki; D N Louis; K von Ammon; I Petersen; P Kleihues; R Y Chung; O D Wiestler; B R Seizinger
Journal:  Cancer Res       Date:  1992-05-15       Impact factor: 12.701

10.  Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli.

Authors:  C A Midgley; C J Fisher; J Bártek; B Vojtĕsek; D Lane; D M Barnes
Journal:  J Cell Sci       Date:  1992-01       Impact factor: 5.285

View more
  19 in total

1.  CHEK2 mutations in primary glioblastomas.

Authors:  Satu-Leena Sallinen; Tarja Ikonen; Hannu Haapasalo; Johanna Schleutker
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

2.  Outcome of 31 intracranial haemangiopericytomas: poor predictive value of cell proliferation indices.

Authors:  V Vuorinen; P Sallinen; H Haapasalo; T Visakorpi; M Kallio; J Jääskeläinen
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

3.  Bcl-2 expression in higher-grade human glioma: a clinical and experimental study.

Authors:  C Fels; C Schäfer; B Hüppe; H Bahn; V Heidecke; C M Kramm; C Lautenschläger; N G Rainov
Journal:  J Neurooncol       Date:  2000-07       Impact factor: 4.130

4.  Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.

Authors:  Joonas Haapasalo; Kristiina Nordfors; Sally Järvelä; Helena Bragge; Immo Rantala; Anna-Kaisa Parkkila; Hannu Haapasalo; Seppo Parkkila
Journal:  Neuro Oncol       Date:  2007-04-13       Impact factor: 12.300

5.  What We Know about the Molecular Genetics of Central Nervous System (CNS) Tumours in Malaysia.

Authors:  Sarina Sulong; Abdul Aziz Mohamed Yusoff; Norafiza Zainuddin; Jafri Malin Abdullah; Jain George Pannatil; Hasnan Jaafar; Mohd Nizam Isa
Journal:  Malays J Med Sci       Date:  2004-01

6.  Accumulation of genetic changes is associated with poor prognosis in grade II astrocytomas.

Authors:  S L Sallinen; P Sallinen; H Haapasalo; J Kononen; R Karhu; P Helén; J Isola
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

7.  Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy.

Authors:  R Kirla; E Salminen; S Huhtala; J Nuutinen; L Talve; H Haapasalo; H Kalimo
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

8.  Mutations and immunohistochemistry of p53 and proliferation markers in astrocytic tumors of childhood.

Authors:  D Schiffer; P Cavalla; A Di Sapio; M T Giordana; A Mauro
Journal:  Childs Nerv Syst       Date:  1995-09       Impact factor: 1.475

9.  p53 protein and epidermal growth factor receptor expression in human astrocytomas.

Authors:  R Kordek; W Biernat; J Alwasiak; R Maculewicz; R Yanagihara; P P Liberski
Journal:  J Neurooncol       Date:  1995-10       Impact factor: 4.130

10.  Increased hMSH2 protein expression in glioblastoma multiforme.

Authors:  Tapasya Srivastava; Parthaprasad Chattopadhyay; A K Mahapatra; Chitra Sarkar; Subrata Sinha
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.